Modus Advisors LLC Purchases 640 Shares of Eli Lilly and Company $LLY

Modus Advisors LLC boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 48.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,952 shares of the company’s stock after acquiring an additional 640 shares during the quarter. Modus Advisors LLC’s holdings in Eli Lilly and Company were worth $1,489,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Sumitomo Mitsui Financial Group Inc. acquired a new stake in shares of Eli Lilly and Company in the second quarter valued at approximately $27,000. Evolution Wealth Management Inc. acquired a new stake in Eli Lilly and Company during the 2nd quarter valued at $29,000. Steph & Co. boosted its position in Eli Lilly and Company by 290.0% during the third quarter. Steph & Co. now owns 39 shares of the company’s stock worth $30,000 after purchasing an additional 29 shares during the period. Financial Gravity Companies Inc. acquired a new position in shares of Eli Lilly and Company in the second quarter valued at $31,000. Finally, Bare Financial Services Inc increased its holdings in shares of Eli Lilly and Company by 263.6% in the second quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock valued at $31,000 after purchasing an additional 29 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 7.8%

Shares of LLY stock opened at $1,020.39 on Friday. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. The stock has a market cap of $964.66 billion, a P/E ratio of 44.46, a price-to-earnings-growth ratio of 0.82 and a beta of 0.39. The stock has a 50 day simple moving average of $1,052.61 and a 200 day simple moving average of $896.17. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. The firm had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a return on equity of 112.50% and a net margin of 31.66%.The company’s revenue was up 42.6% on a year-over-year basis. During the same quarter last year, the company earned $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s payout ratio is presently 29.35%.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Daiwa Capital Markets set a $1,230.00 target price on shares of Eli Lilly and Company and gave the stock a “buy” rating in a report on Tuesday, December 16th. Wall Street Zen downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 31st. National Bankshares set a $1,286.00 price objective on Eli Lilly and Company in a report on Monday, December 1st. Zacks Research lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. Finally, Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $1,201.17.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong Q4 beat and bullish 2026 guidance — Lilly reported a large revenue and EPS beat driven by Zepbound and Mounjaro, and issued FY2026 revenue and EPS guidance well above Street estimates, which triggered the initial rally. Eli Lilly shares soar after Q4 beat, strong forecast on weight-loss drugs
• Positive Sentiment: Analysts raising targets and reaffirming conviction — Multiple firms have bumped price targets and kept overweight/buy ratings after the results, reflecting confidence in GLP-1 demand and Lilly’s runway. JPMorgan price-target raise / coverage summary
• Positive Sentiment: Capacity expansion to support volume growth — Lilly announced a large manufacturing investment (>$3.5B) to boost production capacity, supporting the company’s “volume defense” against U.S. pricing pressure. Lilly to invest over $3.5B in new manufacturing facility
• Neutral Sentiment: Sector context: GLP-1 headlines lift some peers — Pfizer’s positive GLP-1 data and broader industry activity are expanding the market opportunity (good long-term signal) but also increasing near-term competition. Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most
• Neutral Sentiment: Growing divergence with Novo — Coverage notes that Lilly’s execution and capacity have shifted investor expectations relative to Novo Nordisk, which helps explain the recent re-rating. The Metabolic Split: Why Eli Lilly Soars as Novo Stumbles
• Negative Sentiment: Low-cost oral GLP-1 competition from Hims & Hers — News that Hims will offer a compounded oral semaglutide at ~$49/month undercut pricing expectations for branded oral therapies and prompted the post-rally selloff. This raises concerns about price resilience for upcoming oral launches (e.g., orforglipron). Novo Nordisk and Eli Lilly fall after Hims & Hers announce $49 copy of Wegovy pill
• Negative Sentiment: Legal/investor probes — Two investor-alerts/firm investigations (Scott+Scott and Kahn Swick & Foti) were announced regarding management decisions and the proposed Ventyx transaction, adding governance/legal noise that can weigh on sentiment. Scott+Scott investor alert Ventyx / KSF investor alert

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.